Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 2 iu; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis toxoid, quantity: 2.5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu - injection, suspension - excipient ingredients: glutaral; formaldehyde; phenoxyethanol; water for injections; aluminium phosphate - adacel is indicated for active immunisation against tetanus, diphtheria and pertussis in persons aged 10 years and over as a booster following primary immunisation. adacel may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.

Keňa - angličtina - Pharmacy and Poisons Board

sanofi pasteur s.a 1541 avenue marcel merieux 69280 marcy l'etoile, - tetanus toxoid - suspension for injection - each 05ml dose tetanus toxoid 40 iu - bacterial vaccines: tetanus vaccines

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein - liquid - 20mcg; 20mcg; 5mcg; 3mcg; 15lf; 5lf; 40unit; 8unit; 32unit; 10mcg; 30mcg - pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg - vaccines

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertactin; filamentous haemagglutinin; pertussis toxoid; fimbriae types 2 and 3 (fim); inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; tetanus toxoid; diphtheria toxoid - suspension - 3mcg; 20mcg; 20mcg; 5mcg; 26unit; 7unit; 29unit; 5lf; 15lf - pertactin 3mcg; filamentous haemagglutinin 20mcg; pertussis toxoid 20mcg; fimbriae types 2 and 3 (fim) 5mcg; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; tetanus toxoid 5lf; diphtheria toxoid 15lf

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; polyribose ribitol phosphate polysaccharide (prp); tetanus protein - liquid - 20mcg; 20mcg; 5mcg; 3mcg; 15lf; 5lf; 10mcg; 20mcg - pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; polyribose ribitol phosphate polysaccharide (prp) 10mcg; tetanus protein 20mcg - vaccines

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; polyribose ribitol phosphate polysaccharide (prp); tetanus protein - liquid - 10mcg; 5mcg; 5mcg; 3mcg; 15lf; 5lf; 10mcg; 30mcg - pertussis toxoid 10mcg; filamentous haemagglutinin 5mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; polyribose ribitol phosphate polysaccharide (prp) 10mcg; tetanus protein 30mcg - vaccines

Spojené státy - angličtina - NLM (National Library of Medicine)

mcm vaccine co. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37), - vaxelis™ is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to haemophilus influenzae (h. influenzae ) type b. vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). do not administer vaxelis to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of vaxelis, any ingredient of vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis b vaccine, or h. influenzae type b vaccine [see description (11) .] do not administer vaxelis to anyone with a history of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine, that is not attributable to another identifiable cause. do not administer vaxelis to anyone with a history of progressive neurologic disorder, includ

Spojené státy - angličtina - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - quadracel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. a single dose of quadracel is approved for use as a fifth dose in the diphtheria, tetanus, pertussis (dtap) vaccination series, and as a fourth or fifth dose in the inactivated poliovirus (ipv) vaccination series in children 4 through 6 years of age whose previous dtap vaccine doses have been with pentacel® [diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine], daptacel® (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) and/or vaxelis (diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis b vaccine). severe allergic reaction (e.g., anaphylaxis) to any ingredient of quadracel [see description (11) ] or following any diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, or inactivated poliovi

Singapur - angličtina - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (acellular pertussis) filamentous haemagglutinin adsorbed (fha); (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim); (acellular pertussis) pertactin adsorbed (prn); (acelullar pertussis) pertussis toxoid adsorbed (pt); diphtheria toxoid adsorbed; tetanus toxoid adsorbed - injection, suspension - 5 micrograms - (acellular pertussis) filamentous haemagglutinin adsorbed (fha) 5 micrograms; (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim) 5 micrograms; (acellular pertussis) pertactin adsorbed (prn) 3 micrograms; (acelullar pertussis) pertussis toxoid adsorbed (pt) 2.5 micrograms; diphtheria toxoid adsorbed 2 lf; tetanus toxoid adsorbed 5 lf

Spojené státy - angličtina - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37), bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (unii: 8c367iy4ey) (bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) - unii:8c367iy4ey), bordetella pertussis pertactin antigen (unii: 63gd90pp8x) (bordetella pertussis pertactin antigen - unii:63gd90pp8x), bordetella pertussis fimbriae 2/3 antigen (unii: 1o0600285a) (bordetella pertussis fimbriae 2/3 antigen - unii:1o0600285a), poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - pentacel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to haemophilus influenzae type b. pentacel is approved for use as a four dose series in children 6 weeks through 4 years of age (prior to fifth birthday). a severe allergic reaction (eg, anaphylaxis) after a previous dose of pentacel or any other diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine, inactivated poliovirus vaccine or h. influenzae type b vaccine, or any ingredient of this vaccine is a contraindication to administration of pentacel [see description (11) ]. encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including pentacel. progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy is a contraindication to administration of any pertussis-containing vaccine including pentacel. pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized. the safety and effectiveness of pentacel was established in the age group 6 weeks through 18 months on the basis of clinical studies [see clinical trials experience (6.1) and clinical studies (14) ]. the safety and effectiveness of pentacel in the age group 19 months through 4 years is supported by evidence in children 6 weeks through 18 months. the safety and effectiveness of pentacel in infants less than 6 weeks of age and in children 5 to 16 years of age have not been established.